Menopause: Symptoms, Stages, Causes and Complete Treatment Guide
- Dr. Kimryn Rathmell
- Aug 3
- 8 min read
More than 1 million women in the United States reach menopause each year. Every woman who lives long enough will go through it — yet menopause remains one of the most undertreated and misunderstood transitions in women's health. Approximately 80% of women experience menopausal symptoms, and 40–60% rate those symptoms as moderate to severe. Yet only 4–6% of eligible US women are currently prescribed hormone replacement therapy (HRT) — down from a peak of 27% in 1999 — leaving the vast majority to suffer unnecessarily or seek help without clear guidance.
The situation is changing. HRT prescriptions rose 86% between 2021 and the end of 2025, driven by a major re-evaluation of the evidence following the Women's Health Initiative (WHI) study misinterpretation. In 2025, the FDA removed longstanding boxed warnings from certain hormone therapies, and the Menopause Society formally strengthened its guidance supporting early HRT initiation in healthy women under 60. A new non-hormonal medicine — fezolinetant (Veozah) — was FDA-approved in 2023 for hot flashes, the first new class of menopause treatment in decades.
This complete guide covers every stage of menopause, all major symptoms, the biology behind them, and the full 2025 treatment landscape — so you can have an informed conversation with your healthcare provider.
The NIH National Institute on Aging provides comprehensive evidence-based menopause information at: https://www.nia.nih.gov/health/menopause
The Three Stages — Perimenopause, Menopause and Postmenopause
Understanding the three-stage framework is essential for making sense of symptoms and treatment timing:
Perimenopause (the menopausal transition):
Perimenopause is the years-long transition leading up to menopause — typically beginning in a woman's mid-to-late 40s, though it can start as early as the late 30s. During perimenopause, the ovaries begin producing declining and increasingly erratic levels of oestrogen and progesterone. The hormonal rollercoaster — with unpredictable spikes and dips — is what triggers most menopausal symptoms. Periods become irregular — longer, shorter, heavier, lighter, or skipped — and ovulation becomes less frequent. Perimenopause lasts an average of 4–8 years, though it can range from a few months to over 10 years.
Menopause:
Menopause is defined as the point 12 consecutive months after a woman's final menstrual period — not a gradual process, but a single retrospective milestone. The average age at menopause in the USA is 51, with a normal range of 45–55. Early menopause occurs before age 45; premature ovarian insufficiency (POI) before age 40. After menopause, oestrogen levels stabilise at a permanently lower level.
Postmenopause:
All the years following the menopause milestone. While vasomotor symptoms (hot flashes, night sweats) often improve over time for many women, the lower oestrogen state creates ongoing health risks — particularly for bone density (osteoporosis) and cardiovascular health — that persist throughout postmenopause.
Surgical menopause:
Bilateral oophorectomy (removal of both ovaries) at any age causes immediate surgical menopause — an abrupt drop to near-zero oestrogen rather than the gradual perimenopause transition. Symptoms are typically more severe and sudden. Women with surgical menopause under age 51 are strongly recommended to use HRT until at least the natural menopause age.
Symptoms of Menopause — The Full Spectrum
The hallmark symptoms of menopause stem primarily from declining oestrogen — but the symptom spectrum is broader than most women are told:
Vasomotor symptoms (most common and recognised):
Hot flashes — sudden sensation of intense heat spreading through the upper body and face, often with flushing and sweating; typically last 1–5 minutes; occur multiple times per day in moderate-to-severe cases. Vasomotor symptom duration is highly variable — median 7.4 years from onset, and 10.1 years for Black women who experience them more frequently and for longer
Night sweats — hot flashes occurring during sleep; major contributor to sleep disruption and daytime fatigue
Chills — cold sensations following hot flashes as the body overcorrects
Genitourinary Syndrome of Menopause (GSM):
GSM — previously called vaginal atrophy or atrophic vaginitis — is a cluster of genital, sexual, and urinary symptoms caused by oestrogen deficiency in the urogenital tissues:
Vaginal dryness, itching, and irritation
Dyspareunia (painful sexual intercourse) — affects approximately 50% of postmenopausal women
Urinary urgency, frequency, and recurrent UTIs
Stress urinary incontinence
GSM affects approximately half of postmenopausal women and — unlike vasomotor symptoms — does not resolve on its own and worsens progressively without treatment. Only about 7% of women with GSM symptoms ever receive prescription treatment for them.
Sleep disturbance:
Night sweats cause fragmented sleep, but insomnia in menopause has additional mechanisms — direct oestrogen effects on sleep architecture, increased sleep apnea risk, and anxiety. Up to 60% of perimenopausal women report significant sleep problems.
Mood and cognitive symptoms:
Irritability, mood swings, anxiety, and low mood — particularly during perimenopause when oestrogen fluctuates dramatically
Brain fog — difficulty with concentration, word-finding, and memory; documented in neuroimaging studies during the menopausal transition; typically improves after menopause
Musculoskeletal symptoms:
Joint pain (arthralgia) and muscle aches — very common; often attributed to ageing rather than oestrogen loss
Reduced muscle mass and strength
Metabolic changes:
Weight gain — particularly visceral (abdominal) fat redistribution; average 1.5 kg weight gain per year during perimenopause
Worsening insulin resistance
Rising LDL cholesterol and triglycerides; falling HDL
Other symptoms:
Reduced libido — multifactorial: oestrogen, testosterone decline, GSM, mood, relationship factors
Skin thinning and dryness
Hair thinning
Headaches — particularly in women with pre-existing migraines
Palpitations — driven by oestrogen effects on the autonomic nervous system
Health Consequences of Untreated Menopause
Beyond the quality-of-life impact of symptoms, the lower post-menopausal oestrogen state creates lasting health risks:
Osteoporosis:
Oestrogen is critical for maintaining bone density. In the first 5–7 years after menopause, women lose bone density at approximately 2–3% per year — compared to 0.3–0.5% per year in premenopausal women. By age 70, women who have never used HRT have typically lost 25–30% of their peak bone mass. HRT prevents this accelerated bone loss entirely while used.
Cardiovascular disease:
Oestrogen is cardioprotective — it maintains endothelial function, lowers LDL, raises HDL, and reduces arterial inflammation. After menopause, cardiovascular disease risk in women rises to equal men within a decade. The timing hypothesis shows that HRT initiated before age 60 or within 10 years of menopause reduces cardiovascular risk, while HRT started more than 10 years after menopause in older women may not benefit.
Treatment Options — The 2025 Evidence-Based Landscape
1. Menopausal Hormone Therapy (MHT/HRT) — Most Effective for Vasomotor Symptoms
HRT remains the most effective treatment for moderate-to-severe hot flashes, night sweats, and GSM, and the only treatment that simultaneously addresses bone loss and cardiovascular risk when initiated at the right time.
Types of HRT:
Oestrogen-only HRT — for women who have had a hysterectomy; given systemically (patch, gel, pill, spray) or locally (vaginal cream, ring, pessary for GSM only)
Combined HRT (oestrogen + progestogen) — for women with an intact uterus; progestogen protects the endometrium
Transdermal oestrogen (patches, gels, sprays) — preferred route for most women; avoids first-pass liver metabolism; lower VTE risk than oral oestrogen
Testosterone — off-label for low libido/sexual dysfunction in menopause
The WHI clarification:
The 2002 WHI trial caused a 70% drop in HRT prescribing by reporting increased breast cancer and cardiovascular risk. Subsequent re-analysis revealed these risks primarily affected women who started HRT well past menopause (average age 63 in the trial). For women under 60 or within 10 years of their final period — the window of opportunity — the current consensus of all major menopause societies is that the benefits substantially outweigh risks for most women without specific contraindications.
The US Office on Women's Health provides comprehensive HRT and menopause treatment guidance at: https://womenshealth.gov/menopause
2. Fezolinetant (Veozah) — New Non-Hormonal Option
FDA-approved in 2023, fezolinetant is a neurokinin 3 (NK3) receptor antagonist — the first entirely new class of hot flash treatment in decades. It targets the KNDy neurons in the hypothalamus that drive hot flashes without using hormones. Reduces hot flash frequency by approximately 50–60% compared to placebo. Suitable for women who cannot or choose not to use HRT.
3. Non-Hormonal Prescription Options:
SSRIs/SNRIs — Paroxetine (Brisdelle — FDA-approved specifically for menopause hot flashes), Venlafaxine, Escitalopram; reduce hot flash frequency by approximately 40–60%
Gabapentin/Pregabalin — off-label; effective for hot flashes particularly at night; helpful for sleep and mood
Clonidine — alpha-2 agonist; modest hot flash reduction
Local vaginal oestrogen — for GSM specifically; minimal systemic absorption; can be used in women with oestrogen-sensitive cancer history (discuss with oncologist)
4. Lifestyle Approaches:
Regular aerobic exercise — reduces hot flash severity and improves sleep, mood, and bone density
Maintaining healthy weight
Keeping cool — trigger identification (hot drinks, alcohol, spicy food, stress)
Mindfulness and CBT — reduce hot flash distress more than frequency
Calcium (1,000–1,200 mg/day) and Vitamin D (800–1,000 IU/day) — essential for bone health
HRT Options Comparison Table
HRT Type | Route | Best For | VTE Risk | Progestogen Needed? |
Transdermal oestrogen | Patch, gel, spray | Most women — preferred route | Minimal | If uterus intact |
Oral oestrogen | Tablet | Convenient; also lowers LDL | Higher than transdermal | If uterus intact |
Vaginal oestrogen | Cream, pessary, ring | GSM only; very low systemic absorption | Negligible | No |
Combined patch | Oestrogen + progestogen patch | No-pill convenience | Minimal | Already included |
Micronised progesterone | Oral or vaginal | Preferred progestogen — lower breast risk than synthetic | N/A | Required with intact uterus |
Testosterone (off-label) | Gel or cream | Low libido | N/A | No |
Non-Hormonal Treatment Comparison Table
Treatment | Mechanism | Hot Flash Reduction | FDA Approved? | Best For |
Fezolinetant (Veozah) | NK3 receptor antagonist | ~50–60% | ✓ 2023 | HRT-ineligible women; moderate-severe VSM |
Paroxetine (Brisdelle) | SSRI | ~40–60% | ✓ (for menopause) | Mood symptoms + hot flashes |
Venlafaxine | SNRI | ~40–55% | Off-label | Depression/anxiety + hot flashes |
Gabapentin | Calcium channel modulator | ~35–50% | Off-label | Night sweats, sleep disturbance |
Escitalopram | SSRI | ~40–50% | Off-label | Well-tolerated; minimal interactions |
Clonidine | Alpha-2 agonist | ~25–35% | Off-label | When others not tolerated |
Mindfulness/CBT | Psychological | Reduces bother, not frequency | N/A | Symptom distress, not frequency |
For our complete guide to sleep disorders and insomnia — directly linked to menopause: [How to Sleep Better: 15 Proven Tips for Insomnia]
For our guide to depression — frequently misdiagnosed in perimenopausal women: [Depression: Symptoms, Causes and Treatment]
For our complete guide on anxiety disorders — closely linked to the perimenopause transition: [Anxiety Disorders: Types, Symptoms, Causes and Treatment]
The NIA's comprehensive guide to hot flash treatment options is available at: https://www.nia.nih.gov/health/menopause/hot-flashes-what-can-i-do
Frequently Asked Questions
At what age does menopause usually start?
The average age of menopause in the United States is 51, with a normal range of 45 to 55. The onset of perimenopause typically begins 4 to 8 years before the final period, meaning many women begin experiencing symptoms in their mid-to-late 40s. Early menopause occurs before age 45 and premature ovarian insufficiency before age 40. Genetics is the strongest predictor of menopause timing — a woman's mother's menopause age is a reliable guide.
Is HRT safe? What happened with the Women's Health Initiative?
The 2002 WHI study reported increased breast cancer and cardiovascular disease risk with combined HRT, triggering a 70 percent drop in prescribing. Subsequent re-analysis revealed these risks were primarily relevant to older women who started HRT more than 10 years after menopause. For women under 60 or within 10 years of their final period, current consensus from the Menopause Society, ACOG, British Menopause Society, and NICE is that HRT benefits substantially outweigh risks for most healthy women. In 2025 the FDA removed longstanding boxed warnings from certain HRT products.
How long do hot flashes last?
Hot flash duration varies greatly. The median duration from first hot flash to resolution is 7.4 years, but approximately one-third of women continue having hot flashes for more than 10 years. Black women experience hot flashes for a median of 10.1 years — significantly longer. For women with bothersome vasomotor symptoms, treatment is appropriate regardless of time since menopause.
Can menopause cause depression?
Perimenopause is a neurobiologically vulnerable period for mood disorders — risk of a first depressive episode approximately doubles during the menopausal transition. This is driven by oestrogen's effects on serotonin, dopamine, and noradrenaline systems, plus sleep disruption caused by night sweats. Perimenopausal depression often responds to HRT as well as or better than antidepressants when mood symptoms are clearly linked to the hormonal transition.
What is GSM and why is it undertreated?
Genitourinary Syndrome of Menopause (GSM) encompasses vaginal dryness, painful intercourse, urinary urgency, and recurrent UTIs caused by oestrogen deficiency. It affects approximately half of postmenopausal women but only about 7 percent receive prescription treatment. Unlike hot flashes, GSM does not improve over time without treatment and progressively worsens. Effective treatments include local vaginal oestrogen, ospemifene (oral SERM), and vaginal DHEA (prasterone).
Comments